Skip to main content
Terug
Watch Compare

Longevity Health Holdings, Inc.

Datakwaliteit: 100%
Ook genoteerd als XAGEW OTC
XAGE
OTC Manufacturing Chemicals
€ 0,27
▼ € 0,01 (-3,60%)
Marktkapitalisatie: 663.386,0
Prijs
€ 0,27
Marktkapitalisatie
663.386,0
Dagbereik
€ 0,30 — € 0,39
52-Weeksbereik
€ 0,23 — € 9,30
Volume
12.899
Openen € 0,39
50D / 200D Gem.
€ 0,31
13,60% below
50D / 200D Gem.
€ 1,19
77,43% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -3,34 M
Capital efficient — spends only 0,74% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)3701,44%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net Margin-361,00%
Op. Margin-371,58%

Veiligheid

Debt / Equity
N/A
Current Ratio0,42
Interest Coverage-390,23

Waardering

PE (TTM)
-0,10
Boven sectorgemiddelde (-1,47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,1 -1,5
P/B 1,6
ROE % -53,5
Net Margin % -361,0 -41,5
Rev Growth 5Y % 1,8
D/E 0,3

All Fundamental Metrics

Growth
Revenue Growth (1Y) 3701,44% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,91 M Net Income (TTM) -6,91 M
ROE N/A ROA -196,78%
Gross Margin 57,23% Operating Margin -371,58%
Net Margin -361,00% Free Cash Flow (TTM) -3,34 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,42
Interest Coverage -390,23 Asset Turnover 0,55
Working Capital -4,00 M Tangible Book Value -3,99 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,10 Forward P/E N/A
P/B Ratio N/A P/S Ratio 0,35
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -504,00%
Market Cap 663.386,0 Enterprise Value 663.386,0
Per Share
EPS (Diluted TTM) -4,83 Revenue / Share 0,77
FCF / Share -1,35 OCF / Share -1,35
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,74% FCF Conversion 48,42%
SBC-Adj. FCF -4,03 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2021 FY2022
Revenue 1,91 M 50.318,0
Net Income -6,91 M -10,37 M -15,45 M -329.382,0 204.997,0
EPS (Diluted) -4,83 -0,49 -1,46
Gross Profit 1,09 M 43.961,0
Operating Income -7,11 M -5,00 M -5,94 M -467.431,0 -1,65 M
EBITDA
R&D Expenses 788.888,0 1,05 M 2,50 M
SG&A Expenses
D&A 78.675,0 83.486,0 97.113,0
Interest Expense 18.214,0 29.446,0
Income Tax 36.262,0 -97.279,0 0,0 0,0 391.198,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2021 FY2022
Total Assets 2,37 M 1,47 M 63,95 M 155,42 M 156,98 M
Total Liabilities 8,23 M 6,19 M 39,20 M 5,74 M 7,09 M
Shareholders' Equity -5,87 M -4,71 M 24,75 M -4,76 M -6,02 M
Total Debt
Cash & Equivalents 706.740,0 2,91 M 774.192,0
Current Assets 1,95 M 955.554,0 62,90 M 973.175,0 285.202,0
Current Liabilities 7,92 M 5,88 M 38,50 M 330.007,0 1,68 M